$4.44 (1.60%)

Volume: 2.34M

Closed: Mar 29, 2023

Hollow Logo Score: -1.180
CTI BioPharma Stock
$4.44 (1.60%)

Volume: 2.34M

Closed: Mar 29, 2023

Score Hollow Logo -1.180

CTI BioPharma Stock Company Profile

3101 Western Avenue, Suite 800

Seattle WA 98121

206 282 7100


Industry: Biotechnology

Sector: Healthcare

CTI BioPharma


CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE